Metabolic indicators that may be associated with reduced GLP-1 activity include: Persistent elevated blood glucose levels , particularly postprandial (after-meal) hyperglycaemia Difficulty achieving or maintaining a healthy weight despite dietary efforts Increased appetite and reduced satiety after meals, leading to frequent snacking Diagnosis of type 2 diabetes or non-diabetic hyperglycaemia (NDH, sometimes called prediabetes), conditions where GLP-1 response is often blunted Features of metabolic syndrome , including central obesity, hypertension, and dyslipidaemia Individuals may also notice practical symptoms such as feeling hungry shortly after eating substantial meals, experiencing energy crashes following carbohydrate-rich foods, or finding portion control particularly challenging
For localized joint or tendon issues, subcutaneous injection near the injury site delivers high local concentrations while also providing systemic distribution
R.BainS
The Precision Peptide Genetic Test ($99 after your first month of treatment) is also a qualified medical expense, allowing you to personalize your therapy using genetic insights into your GLP1R, GIPR, FTO, and MC4R pathways while preserving HSA funds
